Literature DB >> 20479194

Functional selection of hepatitis C virus envelope E2-binding Peptide ligands by using ribosome display.

Fang Chen1, Yinglan Zhao, Min Liu, Dongqing Li, Hongyan Wu, Haidan Chen, Yongzhe Zhu, Fengling Luo, Jin Zhong, Yidan Zhou, Zhongtian Qi, Xiao-Lian Zhang.   

Abstract

Small peptides that inhibit the hepatitis C virus (HCV) at the stage of viral entry have the potential to serve as attractive antiviral drugs. Ribosome display is a cell-free system for in vitro selection of peptides from large random peptide libraries. Thus, we utilized a ribosome display library technique for affinity selection of HCV envelope protein E2-binding peptide ligands. Through 13 rounds of selection, the ribosome display system generated high-affinity 12-mer peptides, and the selected peptide PE2D (MARHRNWPLVMV) demonstrated the highest specificity and affinity to the HCV E2 protein. Furthermore, amino acids 489 to 508 (YPPRPCGIVPAKSVCGPVYC) of E2 were identified as crucial for binding to PE2D. The selected peptides, especially PE2D, not only dramatically blocked E2 protein binding to hepatocytes but also dramatically inhibited HCV cell culture (HCVcc) entry into hepatocytes. HCVcc and HCV particles from HCV patient serum samples could also be specifically captured using PE2D. Our study demonstrates that the newly selected peptide ligand PE2D holds great promise for developing a new molecular probe, a therapeutic drug specifically for HCV, or an early-diagnostic reagent for HCV surface envelope antigen E2.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20479194      PMCID: PMC2916351          DOI: 10.1128/AAC.01357-09

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  59 in total

Review 1.  The role of the hepatitis C virus glycoproteins in infection.

Authors:  M Flint; J A McKeating
Journal:  Rev Med Virol       Date:  2000 Mar-Apr       Impact factor: 6.989

2.  Ribosome display: selecting and evolving proteins in vitro that specifically bind to a target.

Authors:  Christian Zahnd; Patrick Amstutz; Andreas Plückthun
Journal:  Nat Methods       Date:  2007-03       Impact factor: 28.547

3.  Clinical utility and characteristics of nine anti-HCV antibody screening reagents used in Japan.

Authors:  Mifumi Kita; Matsuo Deguchi; Masanori Kagita; Nori Yoshioka; Eiji Kobayashi; Mikio Watanabe; Seishi Asari; Kiyoharu Yamanaka; Yoshinori Iwatani
Journal:  Clin Lab       Date:  2009       Impact factor: 1.138

4.  Correlation between detection of antibodies against hepatitis C virus in oral fluid and hepatitis C virus RNA in serum.

Authors:  L Cock De; V Hutse; R Vranckx
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-08       Impact factor: 3.267

Review 5.  Hepatitis C virus entry: potential receptors and their biological functions.

Authors:  Laurence Cocquerel; Cécile Voisset; Jean Dubuisson
Journal:  J Gen Virol       Date:  2006-05       Impact factor: 3.891

6.  A novel genetic system to detect protein-protein interactions.

Authors:  S Fields; O Song
Journal:  Nature       Date:  1989-07-20       Impact factor: 49.962

7.  The level of CD81 cell surface expression is a key determinant for productive entry of hepatitis C virus into host cells.

Authors:  George Koutsoudakis; Eva Herrmann; Stephanie Kallis; Ralf Bartenschlager; Thomas Pietschmann
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

8.  Functional selection of vaccine candidate peptides from Staphylococcus aureus whole-genome expression libraries in vitro.

Authors:  Thomas Weichhart; Markus Horky; Johannes Söllner; Susanne Gangl; Tamàs Henics; Eszter Nagy; Andreas Meinke; Alexander von Gabain; Claire M Fraser; Steve R Gill; Martin Hafner; Uwe von Ahsen
Journal:  Infect Immun       Date:  2003-08       Impact factor: 3.441

9.  High-affinity binders selected from designed ankyrin repeat protein libraries.

Authors:  H Kaspar Binz; Patrick Amstutz; Andreas Kohl; Michael T Stumpp; Christophe Briand; Patrik Forrer; Markus G Grütter; Andreas Plückthun
Journal:  Nat Biotechnol       Date:  2004-04-18       Impact factor: 54.908

10.  Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.

Authors:  J G McHutchison; S C Gordon; E R Schiff; M L Shiffman; W M Lee; V K Rustgi; Z D Goodman; M H Ling; S Cort; J K Albrecht
Journal:  N Engl J Med       Date:  1998-11-19       Impact factor: 91.245

View more
  1 in total

1.  Binding of cellular nucleolin with the viral core RNA G-quadruplex structure suppresses HCV replication.

Authors:  Wen-Xiu Bian; Yan Xie; Xiao-Ning Wang; Guo-Hua Xu; Bo-Shi Fu; Shu Li; Gang Long; Xiang Zhou; Xiao-Lian Zhang
Journal:  Nucleic Acids Res       Date:  2019-01-10       Impact factor: 16.971

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.